Balloon-occluded transarterial chemoembolization for hepatocellular carcinoma: History, background, and the roles
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Super-selective lipiodol balloon-occluded transarterial chemoembolization (SSLB-TACE) increases lipiodol accumulation in the targeted nodule. To understand the mechanism of increased accumulation, it is necessary to understand intra-hepatic collateral system and rheology of lipiodol. Although SSLB-TACE is thought to be a promising technique, randomized prospective controlled trials to compare local control rates with conventional super-selective lipiodol (c-TACE) are still lacking. Another problem for SSLB-TACE is change of TACE candidates by development of radiofrequency ablation (RFA) technology. Patients with limited number of small nodules are good candidates for both SSLB-TACE and c-TACE, but these are also good candidates for RFA. Because higher priority is given to RFA, TACE is usually indicated for patients with 4 or more nodules, with large nodule(s), and/or with proximal Glisson attaching nodule(s). However, these cases are known as TACE-refractory, and the chance to perform SSLB-TACE or c-TACE would be markedly decreased in institutions where RFA is aggressively performed. In the past, paradigm shift from non-selective TACE to super-selective TACE occurred, and the goal of SSLB-TACE and c-TACE is prolonged complete remission of the treated nodules while sacrificing small volume of liver parenchyma. But another TACE technique, aiming treatment of wide region (hemi-lobe or more) and effective tumor volume reduction while minimizing liver parenchymal damage, is mandatory in RFA era. For this purpose, we developed a new balloon-occluded TACE without using lipiodol; alternate infusion of cisplatin solution and sparse gelatin slurry was repeated under balloon-occlusion (RAIB-TACE) until stasis of gelatin slurry in proximal hepatic arteries was seen. However, not only RFA but also recent development of molecular targeted drugs strongly influences on the indication and the aim of TACE. The goal and technique of TACE should be properly selected in each era, in each institution, and for each patient.
Abstract
Super-selective lipiodol balloon-occluded transarterial chemoembolization (SSLB-TACE) increases lipiodol accumulation in the targeted nodule. To understand the mechanism of increased accumulation, it is necessary to understand intra-hepatic collateral system and rheology of lipiodol. Although SSLB-TACE is thought to be a promising technique, randomized prospective controlled trials to compare local control rates with conventional super-selective lipiodol (c-TACE) are still lacking. Another problem for SSLB-TACE is change of TACE candidates by development of radiofrequency ablation (RFA) technology. Patients with limited number of small nodules are good candidates for both SSLB-TACE and c-TACE, but these are also good candidates for RFA. Because higher priority is given to RFA, TACE is usually indicated for patients with 4 or more nodules, with large nodule(s), and/or with proximal Glisson attaching nodule(s). However, these cases are known as TACE-refractory, and the chance to perform SSLB-TACE or c-TACE would be markedly decreased in institutions where RFA is aggressively performed. In the past, paradigm shift from non-selective TACE to super-selective TACE occurred, and the goal of SSLB-TACE and c-TACE is prolonged complete remission of the treated nodules while sacrificing small volume of liver parenchyma. But another TACE technique, aiming treatment of wide region (hemi-lobe or more) and effective tumor volume reduction while minimizing liver parenchymal damage, is mandatory in RFA era. For this purpose, we developed a new balloon-occluded TACE without using lipiodol; alternate infusion of cisplatin solution and sparse gelatin slurry was repeated under balloon-occlusion (RAIB-TACE) until stasis of gelatin slurry in proximal hepatic arteries was seen. However, not only RFA but also recent development of molecular targeted drugs strongly influences on the indication and the aim of TACE. The goal and technique of TACE should be properly selected in each era, in each institution, and for each patient.
참고문헌 (31)
- Nakamura H, "Hepatic embolization from the common hepatic artery using balloon occlusion technique", Am J Roentgenol, 145, pp.115~116 (1985)
- Mahvash A, "Temporary balloon occlusion of the common hepatic artery for administration of yttrium-90 resin microspheres in a patient with patent hepatoenteric collaterals", J Vasc Interv Radiol, 23, pp.277~280 (2012)
- Cho KJ, "The peribiliary vascular plexus : the microvascular architecture of the bile duct in the rabbit and in clinical cases", Radiology, 147, pp.357~364 (1983)
- Ekataksin W, "The isolated artery : an intrahepatic arterial pathway that can bypass the lobular parenchyma in mammalian livers", Hepatology, 31, pp.269~279 (2000)
- Sugai Y, "A study of wash-out process of contrast media in balloon occlusion hepatic angiography", Nihon Igaku Hoshasen Gakkai Zasshi, 47, pp.1550~1559 (1987)
- Irie T, "Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization : measurement of balloon-occluded arterial stump pressure", Cardiovasc Intervent Radiol, 36, pp.706~713 (2013)
- Tohma T, "Communicating arcade between the right and left hepatic arteries : evaluation with CT and angiography during temporary balloon occlusion of the right or left hepatic artery", Radiology, 237, pp.361~365 (2005)
- Demachi H, "Simulation model based on non-newtonian fluid mechanics applied to the evaluation of the embolic effect of emulsions of iodized oil and anticancer drug", Cardiovasc Intervent Radiol, 23, pp.285~290 (2000)
- Arai H, "Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma", Hepatol Res, 45, pp.663~666 (2015)
- Ogawa M, "Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug : short-term results", Hepatol Res, 46, pp.E60~9 (2016)
- Yamakado K, "Subgrouping of intermediate-stage(BCLC stage B)hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization", Jpn J Radiol, 32, pp.260~265 (2014)
- Miyayama S, "Ultraselective transcatheter arterial chemoembolization with a 2-F tip microcatheter for small hepatocellular carcinomas : relationship between local tumor recurrence and visualization of the portal vein with iodized oil", J Vasc Interv Radiol, 18, pp.365~376 (2007)
- Kudo M, "Transarterial chemoembolization failure", refractoriness: JSH-LCSGJ criteria 2014 update, 2014, pp.87(Suppl 1), 22~31
- Irie T, "Balloon-occluded trans-arterial chemoembolization technique with alternate infusion of cisplatin and gelatin slurry for small hepatocellular carcinoma nodules adjacent to the Glisson sheath", Biomed Res Int, 2019, pp.8350926~ (2019)
- Murakami T, "Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma : rate and risk factors for local recurrence", Cardiovasc Intervent Radiol, 30, pp.696~704 (2007)
- European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Matsui O, "Small hepatocellular carcinoma : treatment with subsegmental transcatheter arterial embolization", Radiology, 188, pp.79~83 (1993)
- Uchida H, "Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and gelfoam particles for hepatocellular carcinoma", Cardiovasc Intervent Radiol, 13, pp.140~145 (1990)
- Shibata T, "Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors : incidence and risk factors", J Vasc Interv Radiol, 14, pp.1535~1542 (2003)
- Wood TF, "Radiofrequency ablation of 231 unresectable hepatic tumors : indications, limitations, and complications", Ann Surg Oncol, 7, pp.593~600 (2000)
- Irie T, "Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules : retrospective comparison with conventional super-selective TACE", Hepatol Res, 46, pp.209~214 (2016)
- Hatanaka T, "Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma", World J Hepatol, 10, pp.485~495 (2018)
- Dorn DP, "Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function", HPB(Oxford), 16, pp.648~655 (2014)
- Irie T, "Balloon-occluded trans-arterial chemo-embolization technique with repeated alternate infusion of cisplatin solution and sparse gelatin slurry (RAIB-TACE) for large hepatocellular carcinoma nodules more than 7cm in diameter", Biomed Res Int (2020)
- Yamada R, "Hepatic artery embolization in 120 patients with unresectable hepatoma", Radiology, 148, pp.397~401 (1983)
- López-Benítez R, "Analysis of nontarget embolization mechanisms during embolization and chemoembolization procedures", Cardiovasc Intervent Radiol, 32, pp.615~622 (2009)
- Nouso K, "Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan", Br J Cancer, 109, pp.1904~1907 (2013)
- Ivanov AI, "Cisplatin binding sites on human albumin", J Biol Chem, 273, pp.14721~14730 (1998)
- Irie T, "Diameter of main tumor feeding artery of a hepatocellular carcinoma : measurement at the entry site into the nodule", Hepatol Res, 46, pp.E100~4 (2016)
- Irie T, "Creation of small gelatin particles by pumping method for transarterial chemoembolization of hepatocellular carcinoma : analysis of particle size and reproducibility", Jpn J Radiol, 33, pp.790~794 (2015)
- Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3 non-inferiority trial", Lancet, 391, pp.1163~1173 (2018)